Can the Lung Cancer Pie Be Divided into Angiogenic Slices?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 26232370.
- Also identified by DOI 10.1158/1078-0432.CCR-15-1180 and PMC identifier 4668212.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
There are no validated markers for predicting benefit from angiogenesis inhibitors or classifying tumors with distinct angiogenic phenotypes. In patients with non-small cell lung cancer treated with bevacizumab and erlotinib, Franzini and colleagues find that angiogenesis- and hypoxia-associated gene expression signatures predict tumor response and/or clinical outcome, and may define distinct angiogenic patterns.
Medical subject headings
- Lung Neoplasms
- Quinazolines